Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Would you offer adjuvant Abemciclib to ER positive HER2 negative with 1 LN positive, Ki-67 >20%, and low Oncotype?
Tumor 3 cm, grade 2 with Ki-67 25%
Answer from: Medical Oncologist at Community Practice
Yes. The low Oncotype DX RS should not alter the standard use of abemaciclib in this setting.
Sign in or Register to read more
17704
Related Questions
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?
Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
What adjuvant systemic therapy would you give a patient with pN2 nodal relapse of ER+/HER2- breast cancer now s/p ALND, after initial mastectomy, adjuvant TC, and 5 years of endocrine therapy?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?